Barclays analyst Geoffrey Meacham downgraded Acceleron Pharma to Equal Weight from Overweight and lowered his price target for the shares to $45 from $54. Market expectations for luspatercept are now priced into the shares, leaving limited room for upside, Meacham tells investors in a research note.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.